gemcitabine/cisplatin
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.
LUX-Lung 6 : A randomized, open-label, phase III study of afatinib ( A ) versus gemcitabine / cisplatin ( GC ) as first-line treatment for Asian patients ( pts ) with EGFR mutation-positive ( EGFR M+ ) advanced adenocarcinoma of the lung .